摘要
CD7分子是一个含有40 kDa的单链糖蛋白分子,属于免疫球蛋白超家族。CD7分子是人体免疫细胞膜上一类重要的表面标志物,在淋巴细胞发育成熟过程中发挥协同刺激分子受体的作用。CD7分子作为血液系统恶性疾病的肿瘤细胞表面的异常标志物,在急性T淋巴细胞白血病(T-ALL)、T细胞淋巴瘤中呈高表达,约30%急性髓细胞白血病(AML)患者的肿瘤细胞中,可检测到CD7抗原表达。CD7分子被认为与疾病侵袭性、耐药性及不良预后有关。强效化疗、免疫治疗、造血干细胞移植(HSCT)等治疗方案对血液系统恶性疾病的治疗已取得显著成效。尽管如此,上述治疗过程中,血液系统恶性疾病患者仍会出现获得性治疗耐受等情况,而分子靶向免疫治疗为该类患者提供了一种安全、高效、特异性的治疗方案,受到越来越多研究者的关注。将CD7分子作为分子靶向抗肿瘤治疗的新靶点,可能为CD7+复发/难治性血液系统恶性疾病治疗提供新的研究方向。笔者拟就目前有关CD7分子的基础及其临床研究新进展进行综述。
CD7 molecule is a 40 kDa single-chain glycoprotein molecule, belonging to the immunoglobulin superfamily. It is an important surface marker on the human immune cell membrane and plays a role in synergistic stimulation of molecular receptors during lymphocyte development and maturation. As an abnormal marker on the surface of hematological malignant cells, it is highly expressed in acute T-lymphocytic leukemia(T-ALL)and T-cell lymphoma. About 30% of patients with acute myeloid leukemia(AML) have been detected the expression of CD7 antigen in tumor cells. CD7 molecule is thought to be involved with disease invasiveness, drug resistance, and poor prognosis. Potent chemotherapy, immunotherapy, hematopoietic stem cell transplantation(HSCT) and other programs have achieved very significant results in the treatment of hematologic malignant diseases. Despite this, there are still some cases of acquired treatment tolerance during the treatment. Molecular targeted therapy provides a safe, effective, and specific therapy regimen that has received increasing attention in recent years. Using of CD7 molecular as a new target for molecular targeted anti-tumor therapy may provide a new therapeutic direction for CD7-positive relapse or refractory hematological malignant diseases. The article intends to review the current progress in the basic and clinical research of CD7 molecules.
作者
朱欣颖
刘欣
Zhu Xinying;Liu Xin(Department of Hematology, Provincial Hospital Affiliated to Anhui Medical University, Hefei 230001, Anhui province, China)
出处
《国际输血及血液学杂志》
CAS
2019年第5期457-460,F0003,共5页
International Journal of Blood Transfusion and Hematology
基金
安徽省重点研究与开发计划项目(201904a07020102).
关键词
抗原
CD7
血液肿瘤
免疫疗法
分子靶向治疗
嵌合抗原受体
Antigens, CD7
Hematologic neoplasms
Immunotherapy
Molecular targeted therapy
Chimeric antigen receptor
